首页 | 本学科首页   官方微博 | 高级检索  
     

依达拉奉联合羟乙基淀粉治疗进展型脑卒中的临床研究
引用本文:张琳,齐伟哲,许东青. 依达拉奉联合羟乙基淀粉治疗进展型脑卒中的临床研究[J]. 中国医药导刊, 2012, 14(1): 76-77
作者姓名:张琳  齐伟哲  许东青
作者单位:1. 北京市顺义区医院神经内一科,北京,101300
2. 北京市顺义区医院神经内二科,北京,101300
摘    要:目的:观察依达拉奉与羟乙基淀粉联合治疗进展性脑卒中的疗效。方法:将本院收治的94例进展型脑卒中患者随即分为治疗组49例和对照组45例。治疗组使用依达拉奉与羟乙基淀粉联合治疗,对照组使用依达拉奉及生理盐水治疗。对比两组治疗前后神经功能缺损程度评分(NDS)与临床疗效。结果:治疗组神经功能缺损评分与对照组有显著性差异(p<0.01);治疗组总的有效率89.3%,显著高于对照组69.9%(p<0.05),且无明显不良反应。结论:依达拉奉联合羟乙基淀粉治疗进展型脑梗死安全有效。

关 键 词:脑卒中  进展型  依达拉奉  羟乙基淀粉

Clinical Study on Progressive Stroke Treated by Edaravone Combined with Hetastarch
Zhang Lin,Qi Weizhe,Xu Dongqing. Clinical Study on Progressive Stroke Treated by Edaravone Combined with Hetastarch[J]. Chinese Journal of Medicinal Guide, 2012, 14(1): 76-77
Authors:Zhang Lin  Qi Weizhe  Xu Dongqing
Affiliation:1 No.1 Department of Neurology;2 No.2 Department of Neurology,Shunyi District Hospital,Beijing 101300,China)
Abstract:Objective:To observe effects of edaravone and hetastarch on treatment to the progressive stroke.Methods:94 patients with progressive stroke from our hospital were divided ramdomizationally into treatment group of 49 patients and control of 45 patients.In the treatment group,edaravone and hetastarch were administered,and edaravone and saline were used in control group.The neurological deficit scores and curative effects were compared between two groups pre-and pro-treatment.Results:There is a significant difference(p<0.01) in NDS between two groups;A total effective rate is 89.3% in the treatment group and 69.9% in the control group,which is significantly different(p<0.05).Untoward effect was not found in the treatment group.Conclusion:Edaravone and hetastarch can be administered together to treat the progressive stroke,which is proved to be safe and effective.
Keywords:Stroke  Progressive type  Edaravone  Hetastarch
本文献已被 CNKI 万方数据 等数据库收录!
点击此处可从《中国医药导刊》浏览原始摘要信息
点击此处可从《中国医药导刊》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号